MOESM1 of Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
Creators: name: Kosiborod, Mikhail
name: Gomes, Marilia
name: Nicolucci, Antonio
name: Pocock, Stuart
name: Rathmann, Wolfgang
name: Shestakova, Marina
name: Watada, Hirotaka
name: Shimomura, Iichiro
name: Chen, Hungta
name: Cid-Ruzafa, Javier
name: Fenici, Peter
name: Hammar, Niklas
name: Surmont, Filip
name: Tang, Fengming
name: Khunti, Kamlesh
Publisher: name: figshare
Year: 2018
Subjects: subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Science Policy

description: Additional file 1: Table S1. Inclusion and exclusion criteria. DDP-4 dipeptidyl peptidase-4. a≥ 20 years in Japan. bIn Japan, only patients using an oral monotherapy as first-line treatment were included. Table S2. Comparisons between patients for whom either HbA1c or total cholesterol data are unreported, and those with complete HbA1c and total cholesterol data. ACEi angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, ASA acetylsalicylic acid, BMI body mass index, HbA1c glycated hemoglobin, SBP systolic blood pressure, SD standard deviation, TC total cholesterol. aPatients with reported data for all variables included in the hierarchical logistic model. bP values calculated for continuous variables using Student’s t-test, and for categorical variables using the χ2 or Fisher’s exact test, as appropriate. cMinor hypoglycemic event in the previous month or major hypoglycemic event in the previous year. Table S3. Number and proportion of patients with microvascular and macrovascular complications according to country (unadjusted). Percentages were calculated for all patients with data available; unreported data were excluded. UAE United Arab Emirates. Figure S1. Sensitivity analysis including only patients with complete data to assess factors associated with (A) microvascular and (B) macrovascular complications. aRRs adjusted for all variables in the figure with the addition of SBP, total, cholesterol levels and comedication use, using a modified Poisson model with cluster-based sandwich variance estimator as described in “Methods”. RRs for the associations between complication prevalence and SBP, total cholesterol levels, and comedication use are not reported due to reverse-causality. bMinor hypoglycemic event in the previous month or major hypoglycemic event in the previous year. BMI body mass index, CI confidence interval, HbA1c glycated hemoglobin, RR rate ratio. Figure S2. Sensitivity analysis with additional variables for site specialty and patient-reported ethnicity to assess factors associated with (A) microvascular and (B) macrovascular complications. aRRs adjusted for all variables in the figure with the addition of SBP, total, cholesterol levels and comedication use, using a modified Poisson model with cluster-based sandwich variance estimator as described in “Methods”. RRs for the associations between complication prevalence and SBP, total cholesterol levels, and comedication use are not reported due to reverse-causality. bMinor hypoglycemic event in the previous month or major hypoglycemic event in the previous year. BMI body mass index, CI confidence interval, HbA1c glycated hemoglobin, RR rate ratio.